Akaza H, Uemura H, Tsukamoto T, Ozono S, Ogawa O, Sakai H, Oya M, Namiki M, Fukasawa S, Yamaguchi A, Uemura H, Ohashi Y, Maeda H, Saito A, Takeda K, Naito S. (2025). A multicenter phase I/II study of enzalutamide in Japanese patients with castration-resistant prostate cancer. Int J Clin Oncol. 21(4):773-782.
Hussain, M., Fizazi, K., Saad, F., Rathenborg, P., Shore, N., Ferreira, U., & Sternberg, C. N. (2025). Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. New England Journal of Medicine, 378(26), 2465-2474.
Penson, D. F., Armstrong, A. J., Concepcion, R., Agarwal, N., Olsson, C., Karsh, L., & Higano, C. S. (2025). Enzalutamide versus bicalutamide in castration-resistant prostate cancer: the STRIVE trial. Journal of Clinical Oncology, 34(18), 2098-2106.
Perimbeti, S., Jamroze, A., Gopalakrishnan, D., Jain, R., Jiang, C., Holleran, J. L., & Chatta, G. (2025). Phase Ib study of enzalutamide with venetoclax in patients with metastatic castration-resistant prostate cancer. Cancer Chemotherapy and Pharmacology, 95(1), 115.
Tran, C., Ouk, S., Clegg, N. J., Chen, Y., Watson, P. A., Arora, V., & Sawyers, C. L. (2010). Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science, 324(5928), 787-790.